Date:2/6/2013

-Loss from deconsolidation of a variable interest entity (3,442)-(3,442)-Loss from discontinued operations, net of tax(4,842)(1,908)(19,147)(3,722)Loss from discontinued operations attributable to noncontrolling interest(1,184)(1,804)(13,289)(3,377)Loss from discontinued operations attributable to stockholders(3,658)(104)(5,858)(345)Net loss attributable to stockholders$(29,171)$(10,387)$(53,301)$ (36,897)Loss per share attributable to stockholdersBasic and diluted - continuing operations$
(0.35)$
(0.15)$
(0.65)$
(0.52)Basic and diluted - discontinued operations$
(0.05)$
-$
(0.09)$
-Basic and diluted - net loss$
(0.40)$
(0.15)$
(0.74)$
(0.52)Weighted average common shares used in computing loss per shareBasic and Diluted72,87070,69872,43370,481Cost of revenue, selling and marketing, research and development, and general and administrative expenses include stock-based compensation charges as follows:  Cost of revenue $
319$
437$
566$
995Selling and marketing $
327$
51$
547$
380Research and development $
477$
567$
993$
,169General and administrative $
,173$
792$
,945$
2,012 

 Accuray IncorporatedConsolidated Balance Sheets(in thousands, except share amounts) December 31,  June 30, 20122012(unaudited) Assets  Current assets:  Cash and cash equivalents 

$
94,773$
43,504 Restricted cash2,6571,560 Accounts receivable, net of allowance for doubtful accounts 

63,46867,890 Inventories88,83081,693 Prepaid expenses and other current assets 

14,76616,715 Deferred cost of revenue—current7,5094,896 Total current assets272,003316,258 Property and equipment, net 

$
37,20937,458 Goodwill59,38959,215 Intangible assets, net 

36,31749,819 Deferred cost of revenue—noncurrent2
'/>"/>

SOURCE Accuray Incorporated Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Accuray Announces Proposed Offering Of $75 Million Of Convertible Senior Notes
2. Accuray Incorporated to Report Financial Results for Second Quarter Fiscal 2013
3. Accuray Incorporated to Speak at 23rd Annual Oppenheimer Healthcare Conference
4. Accuray Incorporated to Speak at 24th Annual Piper Jaffray Healthcare Conference
5. Accuray Incorporated to Speak at Lazard Capital Markets Healthcare Conference
6. 90 Presentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
7. Accuray Announces Results for Fourth Quarter and Fiscal Year 2012
8. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
9. Accuray to Acquire Morphormics, Inc.
10. Accuray and Erasmus Medical Center Sign Master Research and Collaboration Agreement
11. One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability